Catalyst Wire Dossier Catalyst Wire Dossier

Hematopoietic stem cell BCL11A enhancer gene editing therapy

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Hematopoietic stem cell BCL11A enhancer gene editing therapy, covering 2026-02-03 to 2026-02-03. Get the full timeline:

Most recent: Clinical Trial Update: Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies [Phase 1]

See pricing